@article {235451,
	title = {The antiviral Sofosbuvir against mucormycosis: An in silico perspective},
	journal = {Future Virology},
	volume = {14},
	year = {2019},
	note = {<p>Export Date: 24 May 2024; Cited By: 22</p>
},
	month = {2019},
	pages = {739 - 744},
	abstract = {<p>Aim: Mucormycosis (zygomycosis) is a rare fungal infection that affects humans (40-100\% mortality). Rhizopus oryzae is the primary fungus responsible for 70\% of mucormycosis cases. RNA-dependent RNA polymerase (RdRp) is a vital enzyme accountable for the RNA polymerization process in different organisms, including R. oryzae. Blocking this enzyme has been previously reported as a successful strategy to eradicate viral infections. Materials \&amp; methods: AutoDock Vina is utilized for the calculation of binding affinities of Sofosbuvir, Ribavirin and uridine triphosphate nucleotide to the fungal RdRp model built by homology modeling (no solved structures available). Results: Sofosbuvir shows excellent binding affinity to the fungal RdRp in silico. Conclusion: In this study, R. oryzae RdRp is suggested to be a possible protein target against the nucleotide inhibitor, Sofosbuvir. {\textcopyright} 2019 Future Medicine Ltd.</p>
},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077906898\&doi=10.2217\%2ffvl-2019-0076\&partnerID=40\&md5=d8e967e9e8c19415898fbaaacc0eeca3},
	author = {Elfiky, A.A.}
}
